Study suggests federal drug pricing regulations could harm patients with rare diseases
A report from the Fraser Institute contends the federal government's plan to regulate drug costs could be harmful to individuals with rare or ultra-rare disorders. It is pointed out that 23 orphan drugs available in either the U.S. or the EU aren't